Source comparison
Side Effect Profile: Sustained Elevation vs Acute Spiking
CJC-1295 DAC's primary documented side effects in research models include transient injection-site erythema (10–15% incidence), mild fluid retention during the first 48 hours post-administration, and rare vasomotor flushing. Because the peptide extends natural
This comparison does not assign a generated winner or score.
- CJC-1295 DAC's primary documented side effects in research models include transient injection-site erythema (10–15% incidence), mild fluid retention during the first 48 hours post-administration, and rare vasomotor flushing. Because the peptide extends natural GHRH signalling rather than overriding inhibitory pathways, it does not trigger the orexigenic (appetite-stimulating) response associated with ghrelin receptor activation. Clinical observations published in Growth Hormone & IGF Research noted no significant changes in fasting glucose, insulin sensitivity, or lipid profiles across 12-week CJC-1295 protocols at standard research doses.
- GHRP-6 acetate consistently produces marked appetite stimulation. Ghrelin is the body's primary hunger hormone, and GHRP-6's ghrelin mimicry activates neuropeptide Y and agouti-related peptide neurons in the hypothalamus. Research subjects report hunger onset within 20–40 minutes of GHRP-6 administration, persisting for 60–90 minutes. This is mechanistically unavoidable: the same receptor activation that triggers GH release also signals caloric need. Additional documented effects include transient cortisol elevation (15–30% above baseline at peak GH secretion), mild tachycardia, and water retention. A 2021 comparative study in Peptides found that 38% of subjects using GHRP-6 at 300 mcg 3×/day reported persistent hunger interfering with dietary adherence, compared to 4% with CJC-1295 once-weekly dosing.
- Here's the honest answer: GHRP-6's appetite stimulation isn't a side effect you can mitigate with timing or dose reduction. It's the direct result of ghrelin receptor agonism. If your research protocol involves metabolic studies where caloric intake must remain controlled, GHRP-6 introduces a confounding variable that CJC-1295 does not.